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Abstract
Background: The birth prevalence of congenital heart defects (CHDs) has decreased in Canada and Europe. Recom-
mended intake of folic acid in pregnancy is a suggestive risk-reducing factor for CHDs. We investigated the
association between periconceptional intake of folic acid supplements and infant risk of CHDs.
Methods: Information on maternal intake of folic acid supplements before and during pregnancy in the Medical
Birth Registry of Norway 1999–2009 was updated with information on CHD diagnoses from national health
registers and the Cardiovascular Diseases in Norway Project. The association between folic acid intake and infant
risk of CHD was estimated as relative risk (RR) with binomial log linear regression.
Results: Among 517 784 non-chromosomal singleton births, 6200 children were identified with CHD and 1153 with
severe CHD. For all births, 18.4% of the mothers initiated folic acid supplements before pregnancy and 31.6%
during pregnancy. The adjusted RR for severe CHD was 0.99 [95% confidence interval [CI] 0.86, 1.13] comparing
periconceptional intake of folic acid with no intake. Specifically, RR for conotruncal defects was 0.99 [95% CI 0.80,
1.22], atrioventricular septal defects 1.19 [95% CI 0.78, 1.81], left ventricular outflow tract obstructions 1.02 [95% CI
0.78, 1.32], and right ventricular outflow tract obstructions 0.97 [95% CI 0.72, 1.29]. Birth prevalence of septal
defects was higher in the group exposed to folic acid supplements with RR 1.19 [95% CI 1.10, 1.30].
Conclusions: Periconceptional folic acid supplement use showed no association with severe CHDs in the newborn.
An unexpected association with an increased risk of septal defects warrants further investigation.
Keywords: Norway, cohort study, folic acid supplementation, congenital heart defects, epidemiology.
Introduction
Congenital heart defects (CHDs) are among the most
common birth defects and represent an important
cause of infant morbidity and mortality, affecting 5–13
per 1000 births worldwide.1–3 After decades of increas-
ing prevalence of CHDs believed to be explained by
improved diagnostics and reporting,4,5 several studies
have shown a changing time trend with decreasing
prevalence in Canada and Europe after 1999,6,7 and
also in Norway from 2005.3 This decline in CHDs has
been partly explained by the concurrent introduction
of folic acid food fortification or the increasing use of
periconceptional folic acid supplements. Folic acid is
the synthetic form of folate, which is necessary in
DNA, RNA, and protein synthesis, and therefore
important during fetal development. Periconceptional
intake of folic acid has been shown to reduce the risk
for neural tube defects,8,9 and women worldwide have
been recommended to take folic acid supplements
before conception and in the beginning of pregnancy.
More than 70 countries have also implemented folic
acid fortification of grain products,5,6 whereas health
authorities in Norway have refrained from such forti-
fication and recommended periconceptional use of
Correspondence:
Elisabeth Leirgul, Department of Global Public Health and
Primary Care, University of Bergen, PO box 7804, NO-5020
Bergen, Norway.
E-mail: elisabeth.leirgul@uib.no
bs_bs_banner
391doi: 10.1111/ppe.12212
© 2015 The Authors. Paediatric and Perinatal Epidemiology Published by John Wiley & Sons Ltd.
Paediatric and Perinatal Epidemiology, 2015, 29, 391–400
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
folic acid supplements.10 A possible protective effect
of folic acid supplements on CHDs is, however, con-
troversial. While some studies have reported reduced
risk of CHDs in children whose mothers have taken
multivitamins with folic acid11,12 or pure folic acid sup-
plements,13,14 or after folic acid food fortification,6
other studies have reported no effect on CHDs of folic
acid food fortification.15,16
In the Medical Birth Registry of Norway, informa-
tion on the use of folic acid and multivitamin supple-
ments has been recorded for all women giving birth
since 1999.17 We have taken advantage of Norway’s
national health registries and the Cardiovascular
Disease in Norway project (CVDNOR) to investigate
infant risk of specific types of CHDs among mothers
using folic acid supplements in the periconceptional
period.
Methods
Data sources
The Norwegian National Registry contains demo-
graphic data and vital status on all residents since
1965. Every resident’s unique personal identification
number enables linkage of data between national reg-
istries and other data sources. The Medical Birth Reg-
istry of Norway has since 1967 recorded information
on all births (livebirths and stillbirths, since 1999 ter-
minated pregnancies for fetal reasons, and since 2002
all births from 12th week gestation) on the birth noti-
fication form, including information on the mother’s
health, the course of the pregnancy and delivery, and
the health of the newborn.17 Oslo University Hosp-
ital’s clinical registry for children with heart disease
has registered all children with a heart defect admit-
ted to Oslo University Hospital since 1992.18 The mul-
tipurpose research project CVDNOR19 includes
information on discharge diagnoses retrieved from
the electronic Patient Administrative Systems of all
somatic hospitals in Norway 1994–2009.19 The Cause of
Death Registry records contributing causes of death
from death certificates. Statistics Norway provides
demographic data for all residents, including educa-
tional level, occupation, income, and marital status.20
Case ascertainment and classiﬁcation of congenital
heart defects
Information on CHD diagnoses was retrieved from
the four data sources mentioned above, as published
previously,3 where each child was assigned a cardiac
phenotype with priority corresponding to the timing
of presumed errors in fetal heart development2,3:
heterotaxia; conotruncal defects [d-transposition of the
great arteries (TGAs), tetralogy of Fallot (ToF), double
outlet right ventricle, conoventricular ventricle septal
defect (VSD), common arterial trunk, interrupted
aortic arch (IAA) type B or C]; atrioventricular septal
defect (AVSD); anomalous pulmonary venous return
(APVR); left ventricle outflow tract obstruction (LVOTO)
[coarctation of the aorta (CoA), aortic valve stenosis
(vAS), hypoplastic left heart syndrome (HLHS)]; right
ventricle outflow tract obstruction (RVOTO) [hypoplastic
right heart syndrome (HRHS), tricuspid atresia,
Ebstein anomaly, pulmonary atresia (PA) or atresia of
the pulmonary valve with intact ventricular septum,
valvular pulmonary stenosis (vPS)]; septal defect [VSD
only, atrial septal defect (ASD) only and recorded
from postnatal age 6 weeks or with surgical or percu-
taneous correction, VSD and ASD only]; other complex
heart defect [single ventricle, congenital corrected
transposition of the great arteries (ccTGA)]; patent
ductus arteriosus (PDA) at postnatal age > 6 weeks or
with surgical correction, in livebirths with gestational
age 37 weeks or more (term PDA), or with gestational
age < 37 weeks (preterm PDA); other specified heart
defect; and unspecified heart defect. Severe CHD was
defined as heterotaxia, conotruncal defect, AVSD,
APVR, LVOTO, RVOTO (except valvular pulmonary
stenosis), or other complex defect.
Information on chromosome aberrations and
genetic conditions associated with CHD was retrieved
using ICD codes [8th revision 759.3–759.5, 9th revi-
sion 758.0–759.9, 10th revision D82.1, Q87.1, Q87.2,
Q90.0-Q99.9], van Mierop codes [8000–8004, 8009–
8025, 8072], and by searching the free text fields for
specific disorders (e.g. Down’s syndrome, William’s
syndrome, Noonan’s syndrome).
Folic acid and multivitamin supplementation
Since 1999, the Medical Birth Registry of Norway has
registered maternal intake of periconceptional vita-
mins by using five check boxes on the Birth Registry
notification form from maternity units; for regular use
of folic acid or multivitamins before pregnancy or
during pregnancy, or for no supplement use. The
embryonic cardiac development is 3–7 weeks after
conception, and includes the time period when the
mother likely recognises her pregnancy, with subse-
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quent initiation of folic acid supplementation. We
therefore decided to report risk estimates for CHD by
any use of folic acid before pregnancy and/or during
pregnancy, with or without multivitamin intake,
referred to as periconceptional use of folic acid. Risk
analyses were also performed for the other combina-
tions of folic acid and multivitamin exposure
(Table 1). Over-the-counter folic acid supplements in
Norway contained 0.4 mg folic acid and multivitamin
tablets 0.0–0.2 mg folic acid during the study period
1999–2009.
Other variables
We included the following covariates as confounders
of the association between folic acid intake and infant
CHD risk in the multivariable model; year of birth
(each year), maternal age (<20, 20–24, 25–29, 30–34
and >34 years), parity (0, 1 or ≥2 previous pregnan-
cies), maternal education (≤10, 11–13, 14–16, ≥17 years,
missing (7.8%)), marital status (married/cohabitant,
single/other), maternal smoking (regular/occasional,
non-smokers, did not consent to register smoking
information, missing (2.8%)), and family income
(quartiles of mean income of the adults in the family).
In initial analyses, we evaluated maternal diabetes
(pregestational or gestational) as a confounder;
however, diabetes did not affect the association
between folic acid and CHD, and was not included in
the final adjustment model.
Study population
In the period 1999–2009, 652 977 births were regis-
tered in the Medical Birth Registry of Norway. We
excluded births with chromosomal disorders
(n = 2245), multiple births (n = 23 815), births from in
vitro fertilisation (n = 15 791), and births with mater-
nal epilepsy (n = 4978), in total 41 292 (6.3%) births.
Among the remaining 611 685 births, we excluded
93 901 (15.4%) births without information of folic acid
or multivitamin supplementation (which included the
1442 pregnancies terminated for fetal reasons), leaving
517 784 livebirths and stillbirths for analyses.
Statistical analysis
The association between maternal periconceptional
folic acid supplement use and infant risk of CHD was
reported as relative risk (RR); the risk of CHD among
the exposed divided by the risk of CHD among the
unexposed. Births without maternal intake of folic
acid or multivitamin supplements were used as refer-
ence group. Crude and adjusted relative risks (aRR)
with 95% confidence intervals [CI] were estimated
using binomial log linear regression models with a
log-link function using stata version 13 (Stata Corp.,
Texas, USA).
Results
Among 517 784 individuals, 6200 children had any
type of CHD and 1153 had a severe CHD; the birth
prevalence was 119.7 per 10 000 births and 22.3 per
10 000 births, respectively. In the period, the birth
prevalence increased for total CHD until 2004, and
decreased thereafter (Figure 1). The prevalence for
severe CHD decreased from 2005. Overall, 95 509
(18.4%) mothers had initiated folic acid supplements
Table 1. Maternal use of folic acid or multivitamin supplements before and during pregnancy in 517 784 births, Medical Birth Registry
of Norway, 1999–2009a
Supplement use during pregnancy
Folic acid No folic acid
Supplement use before pregnancy
Multivitamin
No. (%)
No multivitamin
No. (%)
Multivitamin
No. (%)
No multivitamin
No. (%)
Folic acid Multivitamin 32 477 (6.3) 2196 (0.4) 1172 (0.2) 1538 (0.3)
No multivitamin 16 485 (3.2) 36 725 (7.1) 1419 (0.3) 3497 (0.7)
No folic acid Multivitamin 18 539 (3.6) 2572 (0.5) 12 496 (2.4) 1986 (0.4)
No multivitamin 62 170 (12.0) 80 205 (15.5) 28 959 (5.6) 215 348 (41.6)
aLivebirths and stillbirths registered in the Medical Birth Registry with information on supplement use, excluding multiple births, births
from in vitro fertilisation, children with chromosomal disorders, and with maternal epilepsy.
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before pregnancy, 163 486 (31.6%) had started during
pregnancy, 43 441 (8.4%) used only multivitamins in
the periconception period, while 215 348 (41.6%) did
not use any folic acid or multivitamin supplements
(Tables 1 and 2). Initiation of folic acid before preg-
nancy increased from 5.5% of all births in 1999 to
29.1% in 2009, while any periconceptional use of
folic acid increased from 21.7% in 1999 to 74.2% in
2009.
In Table 2, initiation of folic acid supplements
before pregnancy or during pregnancy, use of multivi-
tamins only, and no use of any supplements are
shown by year of birth and maternal characteristics.
Shorter education, younger age, smoking, previous
births, single status, and lower family income were
more frequent in mothers who did not use any folic
acid or multivitamin supplements.
Maternal periconceptional use of folic acid was not
associated with infant risk of severe CHD; the aRR
was 0.99 [95% CI 0.86, 1.13] comparing pregnancies
exposed to folic acid with non-exposed pregnancies
(Table 3). Specifically, aRR for conotruncal defects was
0.99 [95% CI 0.80, 1.22], aRR for AVSD 1.19 [95% CI
0.78, 1.81], aRR for LVOTO 1.02 [95% CI 0.78, 1.32],
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Figure 1. Periconceptional use of folic acid supplements and birth prevalence of severe CHD (heterotaxia, conotruncal defect, AVSD,
APVR, LVOTO, RVOTO except valvular pulmonary stenosis, CoA, other complex heart defect) and any CHD except preterm PDA, by
year of birth, in 517 784 livebirths and stillbirths registered in the Medical Birth Registry of Norway, 1999–2009, excluding multiple
births, births from in vitro fertilisation, children with chromosomal disorders, and with maternal epilepsy. APVR, anomalous pulmo-
nary venous return; AVSD, atrioventricular septal defect; CHD, congenital heart defect; CoA, coarctation of the aorta; LVOTO, left
ventricle outflow tract obstruction; PDA, patent ductus arteriosus; RVOTO, right ventricle outflow tract obstruction.
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Table 2. Birth characteristics according to use of folic acid before or during pregnancy in Norway, 1999–2009
Characteristics
Total birthsa
517 784
Preconceptional
folic acidb
95 509 (18.4%)
Postconceptional
folic acid onlyc
163 486 (31.6%)
Multivitamins
onlyd
43 441 (8.4%)
No use of
supplementse
215 348 (41.6%)
No. % of Births No. (%) No. (%) No. (%) No. (%)
Year of birth
1999 46 520 (9.0) 2563 (5.5) 7558 (16.2) 5783 (12.4) 30 616 (65.8)
2000 48 472 (9.4) 3458 (7.1) 9080 (18.7) 4960 (10.2) 30 974 (63.9)
2001 46 693 (9.0) 4018 (8.6) 10 410 (22.3) 4532 (9.7) 27 733 (59.4)
2002 44 226 (8.5) 4475 (10.1) 11 202 (25.3) 4293 (9.7) 24 256 (54.8)
2003 43 749 (8.4) 6379 (14.6) 12 782 (29.2) 3900 (8.9) 20 688 (47.3)
2004 44 464 (8.6) 8376 (18.8) 13 992 (31.5) 3206 (7.2) 18 890 (42.5)
2005 44 614 (8.6) 9649 (21.6) 15 145 (33.9) 2957 (6.6) 16 863 (37.8)
2006 46 215 (8.9) 12 101 (26.2) 17 444 (37.7) 3523 (7.6) 13 147 (28.4)
2007 48 617 (9.4) 13 946 (28.7) 20 162 (41.5) 3661 (7.5) 10 848 (22.3)
2008 51 142 (9.9) 15 110 (29.5) 21 795 (42.6) 3386 (6.6) 10 851 (21.2)
2009 53 072 (10.2) 15 434 (29.1) 23 916 (45.1) 3240 (6.1) 10 482 (19.8)
Maternal education, y
≤10 98 808 (19.1) 10 038 (10.2) 27 673 (28.0) 10 228 (10.4) 50 869 (51.5)
11–13 167 510 (32.4) 25 160 (15.0) 52 171 (31.1) 13 961 (8.3) 76 218 (45.5)
14–16 129 257 (25.0) 32 425 (25.1) 46 113 (35.7) 8317 (6.4) 42 402 (32.8)
≥17 81 713 (15.8) 23 618 (28.9) 27 933 (34.2) 4657 (5.7) 25 505 (31.2)
Missing data 40 496 (7.8) 4268 (10.5) 9596 (23.7) 6278 (15.5) 20 354 (50.3)
Maternal age, y
<20 12 940 (2.5) 402 (3.1) 3475 (26.9) 1640 (12.7) 7423 (57.4)
20–24 79 284 (15.3) 7390 (9.3) 25 824 (32.6) 7940 (10.0) 38 130 (48.1)
25–29 172 574 (33.3) 31 139 (18.0) 56 181 (32.6) 14 050 (8.1) 71 204 (41.3)
30–34 169 622 (32.8) 38 081 (22.5) 52 764 (31.1) 12 798 (7.5) 65 979 (38.9)
>34 83 348 (16.1) 18 494 (22.2) 25 238 (30.3) 7010 (8.4) 32 606 (39.1)
Missing data 16 (0.0) 3 (18.8) 4 (25.0) 3 (18.8) 6 (37.5)
Maternal smoking
No 357 552 (69.1) 75 196 (21.0) 115 748 (32.4) 28 762 (8.0) 137 846 (38.6)
Yes 94 429 (18.2) 9382 (9.9) 30 093 (31.9) 9777 (10.4) 45 177 (47.8)
No consent 59 007 (11.4) 9911 (16.8) 15 937 (27.0) 4420 (7.5) 28 739 (48.7)
Missing data 6796 (1.3) 1020 (15.0) 1708 (25.1) 482 (7.1) 3586 (52.8)
Parity
0 209 839 (40.5) 39 570 (18.9) 75 789 (36.1) 17 871 (8.5) 76 609 (36.5)
1 186 530 (36.0) 38 025 (20.4) 56 236 (30.1) 14 290 (7.7) 77 979 (41.8)
≥2 121 415 (23.4) 17 914 (14.8) 31 461 (25.9) 11 280 (9.3) 60 760 (50.0)
Marital status
Married/cohabiting 476 209 (92.0) 92 043 (19.3) 150 887 (31.7) 38 861 (8.2) 194 418 (40.8)
Single/other 41 575 (8.0) 3466 (8.3) 12 599 (30.3) 4580 (11.0) 20 930 (50.3)
Family income(quartiles)
1 128 127 (24.7) 12 598 (9.8) 36 160 (28.2) 14 376 (11.2) 64 993 (50.7)
2 130 934 (25.3) 21 176 (16.2) 41 621 (31.8) 10 899 (8.3) 57 238 (43.7)
3 129 512 (25.0) 27 615 (21.3) 42 493 (32.8) 9393 (7.3) 50 011 (38.6)
4 124 504 (24.0) 33 706 (27.1) 42 472 (34.1) 8105 (6.5) 40 221 (32.3)
Missing data 4707 (0.9) 414 (8.8) 740 (15.7) 668 (14.2) 2885 (61.3)
aLivebirths and stillbirths registered in the Medical Birth Registry with information on supplement use, excluding multiple births, births
from in vitro fertilisation, children with chromosomal disorders, and maternal epilepsy.
bInitiation of folic acid supplementation before pregnancy, with or without use of multivitamins.
cInitiation of folic acid supplementation during pregnancy, with or without use of multivitamins.
dMultivitamin supplements before and/or during pregnancy, with no use of folic acid.
ePregnancies with no use of folic acid or multivitamin supplements as reference group.
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and aRR for RVOTO 0.97 [95% CI 0.72, 1.29]. Septal
defects (i.e. ASD, VSD, other septal defects) and term
PDA were associated with increased risk in infants
whose mothers used folic acid, as compared to non-
users; aRRs were 1.19 [95% CI 1.10, 1.30] P < 0.0001
and 1.23 [95% CI 1.01, 1.50] P = 0.04, respectively.
The increased infant risk of septal defects among
folic acid users were similar in categories of maternal
education (≤10 years, aRR 1.26 [95% CI 1.05, 1.52];
11–13 years, aRR 1.09 [95% CI 0.95, 1.26]; 14–16 years,
aRR 1.36 [95% CI 1.15, 1.61]; ≥ 17 years, aRR 1.07 [95%
CI 0.88, 1.30]), year of birth (1999–2002, aRR 1.24 [95%
Table 3. Congenital heart defects according to use of folic acid before and/or during pregnancy in 517 784 births in Norway, 1999–2009a
Heart defect phenotype
Births Any use of folic acidb RR crudec RR adjustedd
No. No. % RR 95% CI aRR 95% CI
Any CHD 6200 3166 (51.1) 1.05 (0.99, 1.10) 1.10 (1.03, 1.16)
CHD excl. preterm PDA 5695 2928 (51.4) 1.07 (1.01, 1.13) 1.13 (1.06, 1.20)
Severe CHD 1153 546 (47.4) 0.89 (0.79, 1.01) 0.99 (0.86, 1.13)
Heterotaxia 71 28 (39.4) 0.69 (0.42, 1.13) 0.80 (0.45, 1.42)
Conotruncal defect 502 240 (47.8) 0.92 (0.77, 1.11) 0.99 (0.80, 1.22)
TGA 179 91 (50.8) 1.07 (0.78, 1.45) 1.10 (0.77, 1.57)
ToF 100 44 (44.0) 0.80 (0.53, 1.20) 0.90 (0.57, 1.44)
Other conotruncale 223 105 (47.1) 0.87 (0.66, 1.15) 0.95 (0.70, 1.30)
AVSD 118 60 (50.8) 0.96 (0.66, 1.39) 1.19 (0.78, 1.81)
APVR 52 21 (40.4) 0.76 (0.42, 1.37) 0.78 (0.40, 1.52)
LVOTO 312 149 (47.8) 0.89 (0.70, 1.12) 1.02 (0.78, 1.32)
HLHS 78 40 (51.3) 0.98 (0.62, 1.55) 1.15 (0.69, 1.94)
CoA + IAA type A 109 53 (48.6) 0.92 (0.62, 1.36) 1.05 (0.67, 1.63)
vAS 125 56 (44.8) 0.80 (0.56, 1.16) 0.92 (0.61, 1.39)
RVOTO 258 120 (46.5) 0.89 (0.69, 1.15) 0.97 (0.72, 1.29)
HRHS 31 17 (54.8) 1.41 (0.65, 3.09) 1.43 (0.59, 3.42)
Ebstein 34 18 (52.9) 1.07 (0.53, 2.15) 0.91 (0.41, 1.99)
vPS 169 75 (44.4) 0.83 (0.60, 1.15) 0.96 (0.67, 1.38)
Other RVOTOf 24 10 (41.7) 0.64 (0.28, 1.46) 0.67 (0.26, 1.74)
Septal defect, isolated 3280 1747 (53.3) 1.16 (1.08, 1.25) 1.19 (1.10, 1.30)
ASD 647 345 (53.3) 1.16 (0.99, 1.37) 1.30 (1.08, 1.56)
VSD 2595 1378 (53.1) 1.15 (1.06, 1.25) 1.16 (1.06, 1.27)
Other septal defect 37 23 (62.2) 1.74 (0.85, 3.57) 1.97 (0.89, 4.38)
Other complex CHDg 9 3 (33.3) 0.50 (0.12, 2.09) 0.70 (0.15, 3.36)
Isolated PDA 1074 543 (50.6) 1.00 (0.88, 1.13) 1.02 (0.88, 1.17)
At term gestation 569 305 (53.6) 1.16 (0.98, 1.38) 1.23 (1.01, 1.50)
Preterm gestation 505 238 (47.1) 0.85 (0.71, 1.02) 0.82 (0.67, 1.01)
Other specified CHD 285 147 (51.6) 1.03 (0.81, 1.31) 1.17 (0.89, 1.53)
Unspecified CHD 239 108 (45.2) 0.80 (0.62, 1.04) 0.84 (0.62, 1.14)
aLivebirths and stillbirths registered in the Medical Birth Registry, excluding multiple births, births from in vitro fertilisation, children
with chromosomal disorders, and with maternal epilepsy.
bPreconceptional or postconceptional initiation of folic acid, with or without use of multivitamins.
cBirths with no periconceptional use of folic acid or multivitamin supplements as reference group.
dRelative risk adjusted for year of birth, parity, family income, mother’s age, education, marital status, and smoking.
eCommon arterial trunk, double outlet of the right ventricle (not ToF anatomy), conotruncal VSD, aortopulmonary window,
supravalvular AS, IAA type B or C.
fValvular or arterial pulmonary atresia.
gSingle ventricle or ccTGAs.
APVR, anomalous pulmonary venous return; ASD, atrial septal defect; AVSD, atrioventricular septal defect; CHD, congenital heart
defect; CoA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; HRHS, hypoplastic right heart syndrome; IAA, inter-
rupted aortic arch; LVOTO, left ventricular outflow tract obstructions; PDA, patent ductus arteriosus; RVOTO, right ventricular outflow
tract obstructions; TGA, transposition of the great arteries; ToF, tetralogy of Fallot; vPS, valvular pulmonary stenosis; VSD, ventricular
septal defect.
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CI 1.09, 1.42]; 2003–2006, aRR 1.19 [95% CI 1.05, 1.35];
2007–2009, aRR 1.10 [95% CI 0.92, 1.32]), and gesta-
tional age (<37 weeks, aRR 1.16 [95% CI 0.94, 1.43];
≥37 weeks, aRR 1.23 [95% CI 1.12, 1.34]).
In Table 4, the aRRs of the main CHD phenotypes
are shown by initiation of folic acid supplementation
before pregnancy (preconception) and during
pregnancy (postconception). For preconceptional or
postconceptional initiation of folic acid, the RRs were
similar for severe defects (aRR 1.10 and aRR 0.97,
respectively) and for septal defects (aRR 1.18 and aRR
1.19, respectively).
Finally, we estimated RR for CHD by various com-
binations of folic acid/multivitamin supplement expo-
sures (folic acid only, folic acid and/or multivitamin
supplement use before pregnancy, before and during
pregnancy, or during pregnancy only) with similar
results to those presented above (results not shown).
Comment
In this nationwide study of 517 784 births and 6200
children with CHD, 50% of the mothers had used folic
acid supplementation in the periconceptional period.
Maternal intake of folic acid supplements was not
associated with infant risk of severe CHD, such as
conotruncal defects, AVSD, LVOTO, and RVOTO.
For septal defects, there was approximately 20%
increased risk in children whose mothers had taken
periconceptional folic acid supplements.
From mid-2000s there has been a decreasing preva-
lence of both severe and non-severe CHD in Norway,
as in other European countries.3,7 This downward time
trend has been suggested explained by the increasing
intake of periconceptional folic acid and multivita-
mins from 1999 to 2009.10 In Quebec, Canada, the dis-
tinct decreasing prevalence of severe CHD from 1999
coincided with implementation of folic acid fortifica-
tion of grain products from 1998.6 In Alberta,
Canada,15 there was a reduction in LVOTO (mainly
CoA) in the post folic acid fortification period, but no
change in the overall CHD prevalence. There was no
corresponding reduction in CHD in Atlanta, Georgia,5
despite a similar food fortification policy. Such corre-
lating time trends of folic acid supplement use or
food fortification and the birth prevalence of CHD in
Table 4. Congenital heart defects according to use of folic acid before and/or during pregnancy in 517 784 births in Norway, 1999–2009a
Heart defect phenotype
Births
Preconceptional
folic acidb (18.4%)
Postconceptional folic
acid onlyc (31.6%)
No. aRRd 95% CI aRRd 95% CI
CHD excl. preterm PDA 5695 1.14 (1.05, 1.24) 1.12 (1.04, 1.20)
Severe CHD 1153 1.10 (0.91, 1.33) 0.97 (0.83, 1.12)
Heterotaxia 71 1.14 (0.52, 2.49) 0.75 (0.39, 1.44)
Conotruncal defect 502 1.30 (0.99, 1.71) 0.90 (0.71, 1.14)
AVSD 118 1.07 (0.59, 1.96) 1.18 (0.75, 1.86)
APVR 52 0.70 (0.27, 1.83) 0.82 (0.42, 1.40)
LVOTO 312 0.93 (0.64, 1.36) 1.06 (0.80, 1.12)
RVOTO 258 0.98 (0.65, 1.47) 0.94 (0.68, 1.25)
Septal defect, isolated 3280 1.18 (1.06, 1.32) 1.19 (1.09, 1.31)
Other complex CHD 9 1.52 (0.24, 9.67) 0.44 (0.05, 3.90)
Isolated PDA at term GA 1074 1.16 (0.88, 1.52) 1.24 (1.00, 1.54)
Other specified CHD 285 1.39 (0.96, 2.01) 1.05 (0.77, 1.42)
Unspecified CHD 239 0.67 (0.43, 1.03) 0.91 (0.65, 1.27)
aLivebirths and stillbirths registered in the Medical Birth Registry, excluding multiple births, births from in vitro fertilisation, children
with chromosomal disorders, and with maternal epilepsy.
bInitiation of folic acid supplementation before pregnancy, with or without use of multivitamins.
cInitiation of folic acid supplementation during pregnancy, with or without use of multivitamins.
dRelative risk adjusted for year of birth, parity, family income, mother’s age, education, marital status and smoking. Births with no
periconceptional use of folic acid or multivitamin supplements as reference group.
APVR, anomalous pulmonary venous return; AVSD, atrioventricular septal defect; CHD, congenital heart defect; GA, gestational age;
LVOTO, left ventricular outflow tract obstructions; PDA, patent ductus arteriosus; RVOTO, right ventricular outflow tract obstructions.
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populations should be interpreted with caution, since
the two events do not necessarily show a causal
relationship.
Only a few studies have reported individual level
information of maternal folic acid supplement use and
infant risk of CHD. A Californian case-control study
from 1995,11 based on telephone interviews with the
mothers of 207 children with conotruncal heart
defects and 481 randomly selected infants without
malformations, reported reduced risk for conotruncal
heart defects in children of mothers who had taken
multivitamins or folic acid fortified cereals. A registry-
based case-control study from the Northern Nether-
lands 1996–2005,13 including 611 children with CHD,
and two control groups; 2401 supposedly non-folate-
related birth defects, and 3343 pregnant women par-
ticipating in previous cross-sectional studies, reported
a reduced risk for CHD, mainly septal defects, in off-
spring of women using periconceptional folic acid
supplements. In these studies, the folic acid content
was similar to the presumed dose in our study
(0.4 mg/d). In a case-control study from Hungary,14
however, much higher doses were used; the estimated
average dose was 5.6 mg/d. This Hungarian study
compared 598 children with CHD born in 1980–1996
with 902 matched controls, 20 896 children with other
malformations, and 38 151 children without birth
defects, and reported a reduced risk for conotruncal
heart defect in the group exposed for folic acid sup-
plements. In a Hungarian randomised controlled
trial,12 multivitamin supplements with 0.8 mg folic
acid were compared to supplements with other trace
elements. There was significantly reduced risk for
CHD in the group receiving vitamins with high-dose
folic acid, but the numbers were small, with only
10 vs. 20 CHD cases in the exposed and unexposed
group, respectively.
A possible risk reduction of CHD by intake of folic
acid or multivitamin supplements is likely deter-
mined by the extent of dietary vitamin insufficiency
in the population. The dietary folate intake reported
in pregnant Norwegian women, around 300 μg per
day,21 could be sufficient for fetal cardiac develop-
ment, as opposed to certain Chinese provinces with a
high prevalence of folate deficiency, where the risk of
CHD has been significantly reduced when mothers
had used periconceptional folic acid supplements.22
Alternatively, the dose of folic acid supplement in
the present study, 400 μg per day, is too small to
prevent cardiac malformations, although plasma
folate has been found to be significantly higher in
women reporting folic acid supplement use.23
However, no risk reduction was found, even in
the group with both folic acid and multivitamin sup-
plements before and during pregnancy (approxi-
mately folic acid dose of 0.6 mg/d), suggesting the
use of folic acid supplements does not prevent CHD
in the Norwegian population. Changes in other risk
factors may explain the recent decrease in CHD
prevalence.
To our surprise, we found a significantly increased
risk for both ASD and VSD if the mother had used
folic acid supplements in the periconceptional period,
which has not been reported previously. The
increased risk of septal defects was not modified by
year of birth, maternal education, or prematurity. The
positive association between folic acid supplements
and risk of septal defects in the present study is
unlikely a chance finding but could be caused by an
unknown residual confounding. A biological factor
cannot be ruled out; in studies of pregnant mice, a
moderate to high intake of folic acid had adverse
effects on offspring cardiac development. Mikael et al.
found that mice fed with a diet containing 10 times
the recommended rodent folic acid intake showed an
increased risk for VSDs and thinner ventricular walls
than the control group.24
The strengths of our nationwide study were the
cohort design, linkage of comprehensive and compul-
sory registries with reliable information, and minimal
loss to follow-up. Ascertainment of CHD cases
through four national administrative and clinical reg-
istries enabled a virtually complete registration of
both severe and minor CHD.3 A weakness may be
related to the validity of the exposure variable, mater-
nal intake of folic acid or multivitamins, as we had no
information on dose or duration of intake. However,
the only folic acid tablets sold in Norway during the
study period contained the recommended daily dose
of 0.4 mg folic acid, and the maximum folic acid
content in multivitamins was 0.2 mg. Although a
large proportion of women started folic acid supple-
mentation during pregnancy in the present study, we
know from another Norwegian study in the same
period that almost all folic acid users had imple-
mented supplementation at 4 to 5 gestational week,
corresponding to 2 to 3 weeks post conception (85 000
pregnancies in the Norwegian Mother and Child
Cohort Study, 2001–2008),25 which should cover most
of the heart development period ranging from 3 to 7
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weeks post conception. All combinations of folic acid
or multivitamin intake before pregnancy or during
pregnancy showed consistent findings; the associa-
tion between folic acid or multivitamin supplement
use and severe CHD was null, and for septal defects,
there was a slightly increased risk after folic acid
supplement use. Other concerns might be lack of
details on additional confounders of the association
between maternal supplementation and maternal/
offspring outcome, such as other dietary nutrients, or
maternal pre-pregnancy weight. We did not have such
information. Information on supplement use was
missing in 15% of all births; these births were
excluded from the study population. However, the
prevalence of severe defects and septal defects
were similar among births with missing folic acid
information and the study population, except for the
terminated pregnancies (0.2% of all births). The preva-
lence of CHD was increased in all terminated preg-
nancies (144 per 1000), but the proportion of
terminated pregnancies among all births with any
CHD (2.7%) or severe CHD (9.3%) was low, and
amounted to a relatively small part of the births with
CHD.
In conclusion, periconceptional use of folic acid or
multivitamin supplements was not associated with
risk of severe CHDs in infants. The association with a
20% increased risk of septal defects may be due to
unknown common factors for folic acid use and CHD
risk, or an adverse effect from folic acid, and warrants
further investigation.
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